Mirum Pharmaceuticals, Inc. (MIRM) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MIRM Revenue Growth
Revenue Breakdown (FY 2025)
MIRM's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
MIRM Revenue Analysis (2018–2025)
As of May 8, 2026, Mirum Pharmaceuticals, Inc. (MIRM) generated trailing twelve-month (TTM) revenue of $409.7 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, MIRM's historical revenue data shows a 3-year CAGR of +89.1%. The company achieved its highest annual revenue of $521.3 million in 2025, representing a new all-time high.
Revenue diversification analysis shows MIRM's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+82.6% YoY), RARE (+13.3% YoY), and ACAD (+9.9% YoY), MIRM has underperformed the peer group in terms of revenue growth. Compare MIRM vs ALNY →
MIRM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MIRMCurrent | $410M | -100.0% | - | -4.2% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% |
MIRM Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $521.3M | +54.7% | $420.7M | 80.7% | $-22,136,000 | -4.2% |
| 2024 | $336.9M | +80.8% | $255.2M | 75.8% | $-87,606,000 | -26.0% |
| 2023 | $186.4M | +141.8% | $139.3M | 74.8% | $-109,154,000 | -58.6% |
| 2022 | $77.1M | +302.7% | $64.7M | 83.9% | $-131,220,000 | -170.3% |
| 2021 | $19.1M | - | $17.2M | 90.1% | $-173,413,000 | -906.1% |
| 2020 | $0 | - | $-623,000 | - | $-104,296,000 | - |
| 2019 | $0 | - | $-324,000 | - | $-54,743,000 | - |
| 2018 | $0 | - | $0 | - | $-2,916,000 | - |
See MIRM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MIRM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MIRM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMIRM — Frequently Asked Questions
Quick answers to the most common questions about buying MIRM stock.
Is MIRM's revenue growth accelerating or slowing?
MIRM revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $410M. This reverses the prior growth trend.
What is MIRM's long-term revenue growth rate?
Mirum Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is MIRM's revenue distributed by segment?
MIRM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.